Clinical Trials Logo
NCT number NCT01453088
Study type Interventional
Source Hackensack University Medical Center
Contact Michele Donato, MD
Phone 201-996-5900
Email MDonato@humed.com
Status Recruiting
Phase Phase 2
Start date June 2010
Completion date December 2015

Clinical Trial Summary

In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.


Clinical Trial Description

In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.

Conditioning Regimens:

Treatment arm A Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.

Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.

Dosing will be based on body surface area calculated using actual body weight

Stem cell infusion:

Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.

Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).

Treatment arm B

Bortezomib:

Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.

Dosing will be based on actual body weight. Dexamethasone is administered at a dose of 20 mg IV prior to each bortezomib infusion.

Melphalan:

Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.

Melphalan will be given as a single dose (not split over 2 or more days) and given of day-2.

Dosing will be based body surface area calculated using actual body weight

Stem cell infusion:

Stem cell infusion will occur on day 0 and will be at least 18 hours after the infusion of the bortezomib. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.

Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).

Post-transplant Supportive Care will be administered in accordance to the Blood and Marrow Transplant program standard operating procedures.


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
 Not yet recruiting NCT02843074 - Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients Phase 2
 Not yet recruiting NCT02757326 - ABC294640 in Refractory / Relapsed Multiple Myeloma Phase 1/Phase 2
 Not yet recruiting NCT02811978 - Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 3
 Not yet recruiting NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic Transplant Phase 1
 Not yet recruiting NCT02892383 - Quality of Life the Danish Multiple Myeloma Patients N/A
 Not yet recruiting NCT02906332 - Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Phase 2
 Not yet recruiting NCT02863991 - Oral ONC201 in Relapsed/Refractory Multiple Myeloma Phase 2
 Not yet recruiting NCT02898064 - Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace N/A
 Not yet recruiting NCT02852837 - Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy Phase 1
 Recruiting NCT02499081 - UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Phase 2
 Recruiting NCT02575144 - GEM-CLARIDEX: Ld vs BiRd Phase 3
 Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
 Recruiting NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1
 Recruiting NCT02541383 - A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Phase 3
 Recruiting NCT02902900 - An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice N/A
 Recruiting NCT02384083 - Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Phase 1/Phase 2
 Recruiting NCT02412878 - A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW) Phase 3
 Recruiting NCT02506959 - Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Phase 2
 Active, not recruiting NCT02566265 - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Phase 2